A tool at Brigham and Women’s Hospital allows clinicians to view profiles of patients with multiple sclerosis (MS) as a snapshot to better understand their overall disease course, said Tanuja Chitnis, MD, associate neurologist at Brigham and Women’s Hospital and professor of neurology at Harvard Medical School.
A tool at Brigham and Women’s Hospital allows clinicians to view profiles of patients with multiple sclerosis (MS) as a snapshot to better understand their overall disease course, said Tanuja Chitnis, MD, associate neurologist at Brigham and Women’s Hospital and professor of neurology at Harvard Medical School.
Transcript
Can you explain the MS profile tool that you use to provide a snapshot of patients’ status? What information does it capture and how is the snapshot used in treatment?
At the Partners Multiple Sclerosis Center at Brigham Women’s Hospital, we’ve developed a tool, which is called MS Patient Profile, and this is really built from our CLIMB [Comprehensive Longitudinal Investigations at the Brigham Women’s Hospital] Study, where we are collecting very detailed clinical information, information about relapses, treatment, disability scores, as well as MRI [Magnetic Resonance Imaging] measures.
And using all of this information, we’ve creating a graph, basically a view in which we can see relapses and treatments and also the change in MRI measures, including brain atrophy and T2 lesions. And this helps to provide just a snapshot to clinicians who are treating patients to understand their overall disease course: is this someone who has responded to treatments? What types of treatments? And overall, are they more or less inflammatory?
We’re hoping to add in additional biomarkers and we’re actively working on this and this could be a decision-making tool for clinicians. And so, that is an active research project.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More